The use of dupilumab for the treatment of recalcitrant brachioradial pruritus

Abel, Mary Kathryn; Ashbaugh, Alyssa G.; Stone, Honor Fullerton; Murase, Jenny E.

doi:10.1016/j.jdcr.2021.02.005

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A clinical exploratory study evaluating dupilumab in cholestatic pruritus is currently recruiting (NCT04256759). Efficient treatment of localized pruritus was reported for a case of neuropathic brachioradial pruritus [ 93 ] and a case of anal and genital pruritus ( Table 2 ) [ 94 ].…”

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

Pruritus in the Elderly: Differential Diagnosis and Management

Shams,

Lipner,

Sayed

2024

Curr Geri Rep

View full text Add to dashboard Cite

Dupilumab: Newer off-label dermatological indications and clinical implications - Part II

Bubna,

Viplav

2024

JSSTD

View full text Add to dashboard Cite

Dupilumab, initially approved for atopic dermatitis, has demonstrated promising efficacy in various off-label dermatological conditions. This part 2 review explores the growing evidence supporting its use in conditions such as lichen planus, Lichen planus pemphigoids, Kimura’s disease, chronic pruritus, and many others. The mechanisms of action, clinical outcomes, and safety profiles associated with dupilumab in these off-label indications are also discussed. As research continues to evolve, dupilumab’s potential as a versatile therapeutic option for dermatological disorders becomes increasingly apparent.

show abstract

The use of dupilumab for the treatment of recalcitrant brachioradial pruritus

Cited by 3 publications

References 9 publications

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Pruritus in the Elderly: Differential Diagnosis and Management

Dupilumab: Newer off-label dermatological indications and clinical implications - Part II

Contact Info

Product

Resources

About